PEPTIDES CONTAINING AN ARGININE MIMETIC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS

Abstract: The present invention is directed to compounds of general formula (I), wherein R1, R2, R3 and X may be the same or different, and wherein R1, R2 represent hydrogen, an amino acid, peptidyl, alkyl or aryl residue; R3 represents hydroxy, lower alkoxy, or an -NR31R32 residue, where R31, R32 represent independently hydrogen, an aminoacid, peptidyl, alkyl or aryl residue; X represents an amino acid or a peptide; R4 represents hydrogen, hydroxy, amino or C1-C4 alkyl; m represents a number between 0 and 5; R5 represents an optionally substituted saturated or unsaturated mono- or bicyclic moiety which may contain one or more heteroatoms, a C1-C11 alkyl group which may have substitutions or intermittent heteroatoms, their tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs as well as their production and their use as medicaments.

Description: PEPΗDES CONTAINING AN ARGININE MIMEΗC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS The present invention relates to new peptide mimetics for the treatment of bone disorders, methods for their production, and drugs containing these compounds. In healthy individuals, the formation and degradation processes in the bones are virtually at equilibrium, i.e., the activity of the osteoblasts and osteociasts is balanced. However, if this equilibrium is disturbed in favor of the osteociasts and/or to the disadvantage of the osteoblasts, a reduction in bone mass and a negative change in bone structure and function will be the result. Up to now, bone resorption inhibitors such as estrogens, calcitonin and bisphosphonates are primarily used in the treatment of bone metabolic disorders. However, the use of these substances is limited and in addition, does not show the desired effect in all of the cases. Compounds having a stimulating effect on bone formation and contributing to increase an already diminished bone mass are therefore of particular importance in the treatment of bone disorders. It is known that PTHrP(107-l l l) and the peptide derivatives thereof have a positive influence on the inhibition of bone resorption (WO 9210511 ; WO 9424153). However, Valin et al. in J. Cell Physiol. 170(2 209-15 (1997), describe an anti-proliferative effect of PTHrP(107-l l l) on UMR106 ceils. Whitfield et al. in J. Cell PhysioL 166(1), 1-11 (1996), demonstrate a stimulating effect on the P C and a modulation of keratinocyte proliferation by PTHrP(107-l l l), whereas Kali et al. in Endocrinology 136(3), 842-8 (1995), describe a stimulation of the osteociasts by PTHrP(107-l 11). Surprisingly, it has now been found that the peptide mimetics of the present invention have a stimulating effect on bone formation and thus, are suitable for the general treatment of bone disorders. In particular, they can be used quite well in those cases where bone formation is disturbed, i.e., they are particularly suited for the treatment of osteopenic diseases of the skeletal system, such as osteoporosis, brittle bone disease among others, as well as for the local promotion of bone regeneration and osteoinduction as, e.g., in orthopedic and orthodontic indications, in fracture curing, osteosyntheses, pseudarthroses and for bone implants to become incorporated. Due to these properties, they are also used in the prophylaxis of osteoporosis. Moreover, due to their influence on the bone metabolism, drugs containing the peptide mimetics of the present invention as active substances constitute a basis for the local and systemic treatment of rheumatoid arthritis, osteoarthritis and degenerative arthrosis. The present invention is directed to compounds of general formula (I) wherein K\, R-2, F-3 and X may be the same or different, and wherein K\, R2 represent hydrogen, an ammo-acid, peptidyl, alkyl or aryl residue; R3 represents hydroxy, lower alkoxy, or an -NR 3 ιR 3 residue, where R31, R32 and represent idependently hydrogen, an aminoacid, peptidyl, alkyl or aryl residue; X represents an amino acid or a peptide; R4 represents hydrogen, hydroxy, amino or Cι-C 4 -alkyl; m represents a number between 0 and 5; R5 represents an optionally substituted saturated or unsaturated mono- or bicyclic moiety which may contain one or more heteroatoms, a C \ -C \ \ alkyl group which may have substitutions or intermittent heteroatoms; their tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs. X is preferably a ω- Amino acid or the dipeptide serinylalaryl; R represents preferably methyl or hydroxy; \ and Ro are independently of each other preferably hydrogen; R3 is preferably hydroxy or amino; m is preferably 1 to 3, more preferably 1; The residue (CHR4)mR5 represents especially preferred a residue attached to C α of a proteinogenic or non-proteinogenic amino acid. Alkaline salts, earth alkaline salts like Ca or Mg salts, ammonium salts, acetates or hydrochlorides are mainly used as pharmacologically acceptable salts which are produced in the usual manner e.g. by tritrating the compounds with inorganic or organic bases or inorganic acids such as e.g. sodium hydroxide, potassium hydroxide, aqueous ammonia, C i-C4-alkyl-amines such as e.g. triethylamine or hydrochloric acid. The salts are usually purified by reprecipitation from water/acetone. Prodrugs of the compounds of the invention are such which are converted in vivo to the pharmacological active compound. The most common prodrugs are carboxylic acid esters, like ethylesters Peptidyl represents are peptide residue. Peptide is understood to be a residue consisting of 2 to 10 proteinogenic or non-proteinogenic identical or different amino acids. Peptides having 2-5 amino acids are preferred; particularly preferred are those having 2 amino acids. Amino acid residue normally means the residue of a proteinogenic or non-proteinogenic amino acid. Non-proteinogenic amino acids are understood to be α-, β-, γ-, and ω -aminocarboxylic acids which may optionally have substitutions or intermittent heteroatoms. Preferred ω-amino acids are -HN-(CH 2 ) n -CO- with n = 1-10; the -(CH 2 ) n -group may be branched or unbranched. Examples of such amino acids are the L- and D-amino acids, like 2-amino-3-hydroxy-4- methylpen t anoic acid , 2-amino-3-hydroxy-4-methylpentanoic acid, 2-amino-3- me t hoxybutanoic acid, 2,3-diaminopropionic acid , 2-amino-2-methyl-3- hydroxypropanoic acid, 2-amino-2-methylbutanedioic acid, 2-amino-3-hydroxy-3- methylbu t anoic acid, 2-amino-3-hydroxy-3-methylbutanoic acid, 2,3-diaminopropionic acid , 2-amino-2-methyl-3-hydroxypropanoic acid, 2-amino-2-methylbutanedioic acid, 2- amino-2-methylbutanoic acid , 2-amino-2-methyl-4-ρentenoic acid , 2-amino-3- methoxypropanoic acid, 1 -amino- 1-cyclohexanecarboxylic acid, 1 -amino- 1- cyclopen t anecarboxylic acid, 1-aminocyclobutanecarboxylic acid, 1- aminocyclopropanecarboxylic acid, 2-(2-furyl)glycine, 2-amino-3-fluorobutyric acid, 2- aminoisobutyric acid, 3-chloroalanine, 3-fluoronorleucine. 3-fluorovaline, 3- fluoroaianine , 3-methoxyvaline, alpha-cyanoaianine, alpha-methyileucine. beta- chloroalanine , beta-cyanoalanine, beta-hydroxyleucine, beta-hydroxyaspaπic acid, 3- hydroxyaspartic acid, 2-aminobutyric acid, allylglycine, gamma-methylleucine, homoserine, norleucine, norvaline, tert-leucine, 2,3-diaminopropionic acid , 2,3- diaminosuccinic acid, 2-amino-4-pentenoic acid, 2-aminobutyric acid, 2-aminoheptanoic acid, 2-cyclopropyl-2-methylglycine, 4-thiaisoleucine, allothreonine, alpha-methylaspartic acid, alpha-methylserine, beta-hydroxynorvaline, beta-methylaspartic acid, homocysteine, homoserine, norleucine, norvaline, O-methylserine, penicillamine, propargaylglycine, beta-hydroxyaspartic acid vmylgtyctne, beta-hydro^'aspartic acid, H-4,5-dehydro-LEU- OH, H-alpha-MeVAL-OH, H-propargayl-GLY-OH, H-allo-ILE-OH, H-PRA-OH, H- trans-4,5-dehydroLYS-OH, 3 -hydroxy aspartic acid, 6-hydroxynorleucine, allo- isoleucine, allyl glycine, alpha-amino-N-butyric acid, gamma-methylleucine, homoserine, norvaline, penicillamine, tert-leucine, vinylglycine, meso-alpha,beta-diaminosuccinic acid, O-carbamoyl-serine, S-methylcysteine, 2-amino-2-methylbutanedioic acid, 2-fluoro-beta- alanine , beta-alanine. beta-aminobutyric acid, 2,3-diaminosuccinic acid, beta- aminoisobutyric acid, isoserine, Preferred amino acids are alanine, serine, tryptophan, tyrosine, phenyialanine, threonine, histidine, citrulline, homocysteine, homoserine, hydroxyproline, hydroxylysine, ornithine, sarcosine, tranexamic acid, Cha (cyclohexylalanine), aminobutyric acid, aminovaleric acid, and aminopropionic acid. Lower alkoxy denote methoxy, ethoxy, propoxy, isopropoxy or butoxy, preferably methoxy. Alkyl normally means linear or branched alkyl residues having from one to six carbon atoms. Aryl normally means a carbocyclic moiety having from 6 to 14 C atoms or a 5- or 6- membered heterocyclic moiety having 1, 2 or 3 heteroatoms selected from O, N, S, which moiety may optionally have one or multiple substitutions, with unsubstituted or optionally substituted phenyl or naphthyl residues being preferred. Monocyclic moiety is understood to be a saturated or unsaturated ring system having 3- 8, preferably 5-7 carbon atoms, which may optionally have one or multiple intermittent heteroatoms such as nitrogen, oxygen or sulfur, particularly a cyclopentyl, cyclohexyl, cycioheptyl, morpholinyl, thiamorpholinyl, piperidinyi, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, or 1,2,4-triazolyl residue. In particular, lower alkyl, alkoxy and halogen are possible as substituents. Preferably, the bicyclic moiety referred to under R5 is a residue such as a naphthyl, tetrahydronaphthyl, decalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydrόisoquinolinyl, indolyl, benzimidazolyl, indazoiyl, oxindolyl, benzofuranyl, benzothiophenyl, benzothiazolyl, benzoxazolyl or purinyl residue, but particularly an indolyl, naphthyl, benzimidazolyl, quinolinyl, tetrahydroquinolinyl, benzothiophenyl, and benzofuranyi residue. The term "several" means in connection with heteroatoms in monocycles or bicycles preferred one, two or three more preferred one or two, the most preferred heteroatom is nitrogen. The term "several" means in connection with substituents or substitution preferred one to five, more preferred one, two or three most preferred one or two. Substitutions of monocycles or bicycles in R 5 are halogen, nitro, hydroxy, alkoxy, amino, alkylamino, dialkylamino, halogenmethyl, dihalogenmethyl, trihalogenmethyl, phosphono, alkylphosphono, dialkylphosphono, SO 2 NH 2 , SO 2 NH(alkyl), SO 2 N(alkyl) 2 , SOj(alkyl), acetyl, formyl, nitril, COOH, COOalkyl, -OC(O)alkyl, -NHC(O)Oal yl, OC(O)O-aryl, -NHC(S)NH 2 , -NHC(S)NHalkyl, -NHC(O)-aryl. Preferred substituents are methyl, ethyl, propyl, isopropyl, halogenyl, especially chloro, amino, acetyl, alkylamino, dialkylamino, alkoxy, hydroxyaikyl, and C0-C4 alkylcarbonic acids. The preparation of the compounds of general formula (I) is achieved according to per se known methods. Advantageously, the preparation is effected using the precursors (II), (III) and (IV), respectively, wherein Y represents a carboxyl group, according to the procedure outlined in Schemes 1, 2 and 3. Compounds of general formula (IV) are new and useful for orthogonal syntheses of compounds which comprise the backbone structure of (IV). The preferred residue for R 9 is Fmoc. Scheme 1 0) (2) (3) (4) d) (7) (6) (5) MHal/OMSO R^N cαoH (12) (9) (1 1) Steps a) through d) in Scheme 1 represent the following reactions: a) NaBH 3 CN/MeOH/RT; b) PhCOCl/py/DMAP/RT; c) DBU/toluene/RT/16 hrs; d) DffiAL-H/THF/-78°C; wherein Rg represents a protecting group, e.g., the benzoyl group, an alkyloxycarbonyl group or the benzyloxycarbonyl group, and Rγ represents hydrogen or lower alkyl such as methyl, ethyl, propyl, butyl or tert-butyl, Rg represents an alkyl or aryl residue such as a methyl, ethyl, trifluoromethyl, phenyl, tosyl or the 4-nitrophenyl residue, but preferably the methyl or tosyl residue, and L normally represents a suifonic acid residue such as the methane- or trifluoromethanesulfonic acid or the p-toluenesulfinic acid residue, or halogen such as chlorine, bromine, iodine, or acetate. MHal represents a metal halide such as NaCl, NaBr, KI, MgCl2 or MgBr2- Compounds of formula (5) have been described (J.O.C. 48, 1129-31 (1983)). The conversion of an alcohol of formula (5) to a suifonic or acetic ester of formula (6) is effected according to standard procedures. The transformation of an alcohol of formula (5) into a halide of formula (6) using N-chloro-, N-bromo- or N-iodosuccinimide (NCS, NBS, NIS) in the presence of triphenyiphosphine (Ph3P) is performed in analogy to the corresponding literature procedures (e.g., Tetrahedron Asym. 4, 1619-24 (1993)). The decarboxylation of malonic esters using metal halides in DMSO at elevated temperatures is well-known (T.L. 957 (1973)). Compounds of formula (9) have been described (JACS 114, 7324-25 (1992)). The epoxide opening of a compound of formula (10) to yield an allyl alcohol of formula (11) is carried out in analogy to the literature (Tetrahedron 24, 5827-30 (1968)). The conversion of a compound of formula (T3 To a compound of general formula (II) by means of a Claisen rearrangement is performed in analogy to the literature (Tetrahedron 52, 941-54 (1996)). Scheme 2 .COOR, c) N^Ph P (16) (19) (18) (17) 0 Steps a) through f) in Scheme 2 represent the following reactions: a) Ac2θ/pyridine/DMAP b) 4 N HCI/16 hrs; ( 14)/EtN(i-Pr) 2 c) ( 16), R 7 = Et/HMDS/n-BuLi/-78°C d) 1 N HCl/THF/RT/30 minutes e) Boc2θ EtN(i-Pr)2/acetonitrile/ 16 hrs 0 LiOH/THF-MeOH-H 2 O wherein Rg and R7 have the above-mentioned meanings. Scheme 3 ( 16) (6) (20) (21) c) Steps a) through e) in Scheme 3 represent the following reaαions: a) HDMS/n-BuLi/-78°C b) CH3COOH/THF/RT/3O minutes c) R 9 Cl/EtN(i-Pr)2/TH /16 hrs d) 4 N HCl/dioxane e) EtN(i-Pr)2/acetonitrile wherein R $ and R7 have the above-mentioned meanings and R9 represents another protecting group such as Fmoc or Troc. The compounds of formula (I) may be administered in liquid or solid form or as aerosols on the oral, enteral, parenteral, topical, nasal, pulmonary or rectal routes in all the common non-toxic, pharmaceutically accepted carriers, adjuvants and additives. The compounds of formula (I) may also be applied locaily on/in bones (optionally with surgical operation). The term "parenteral" includes subcutaneous, intravenous and intramuscular suppiy or infusions. Oral administration forms may be, e.g., tablets, capsules, coated tablets, syrups, solutions, suspensions, emulsions, elixirs, etc., which may contain one or more additives from the following groups, e.g., flavoring substances, sweeteners, colorants, and preservatives. Oral administration forms contain the active component together with non-toxic, pharmaceutically accepted carriers suitable for the production of tablets, capsules, coated tablets, etc., such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; starch, mannitol, methylcellulose, talc, highly dispersed silicic acids, higher molecular weight fatty acids (such as stearic acid), peanut oil, olive oil, paraffin, Miglyol, gelatin, agar-agar, magnesium stearate, beeswax, cetyl alcohol, lecithin, glycerol, animal and vegetable fat, solid high molecular weight polymers (such as polyethylene glycols). Tablets, capsules, coated tablets, etc. may be provided with an appropriate coating such as glyceryl monostearate or glyceryl distearate, so as to prevent undesirable side effects in the stomach, or to result in prolonged activity due to delayed absorption in the gastrointestinal tract. Sterile injectable aqueous or oiiy solutions or suspensions are preferably used as injection media, which contain common additives such as stabilizers and solubilizers. Such additives may be, e.g., water, isotonic saline solution, 1,3- butanediol, fatty acids (such as oleic acid) mono- and digiycerides, or Miglyol. For rectal administration, all the suitable non-irritating additives may be used which are solid at normal temperatures and liquid at rectal temperature, such as cocoa butter and polyethylene glycol. For aerosol administration, the pharmaceutically common carrier media are used. For external application, creams, tinctures, gels, solutions or suspensions with pharmaceutically common additives are used. The dosage may depend on various factors such as the mode of application, species, age and/or individual condition. The doses administered daily or at intervals are around 1-1000 mg/person, preferably around 10-250 mg/person and may be ingested at one go or distributed over several times. The compounds of formula (I) may be applied locally on/in bones (optionally with surgical operation). The application directly on/in bones (optionally with surgical operation) may be effected either in solution or suspension, conveniently by infusion or injection, locally or carrier-bound. For example, carrier-bound compounds of formula (I) may be applied as gels, pastes, solids or as coating on implants. As carriers, biocompatible and preferably, bio-degradable materials are used. Preferably, the materials themselves will additionally induce wound healing or osteogenesis. For local application, it is preferred to embed the compounds of formula (I) in polymeric gels or films, thereby immobilizing them, and to apply these preparations directly on the point of the bone to be treated. These polymeric base gels or films consist of, e.g., glycerol, methylcellulose, hyaluronic acid, polyethylene oxides and or polyoxamers. Collagen, gelatin and alginates are also suitable and are described in WO 93/00050 and WO 93/20859, for example. Other polymers are polylactic acid (PLA) and copolymers of lactic acid and glycolic acid (PLPG) (Hollinger et al., J. Biomed. Mater. Res. 17, 71-82 (1983)), and the "Demineralized Bone Matrix" (DBM) bone derivative (Guterman et al., Kollagen Rel. Res. 8, 419-4319 (1988)). Polymers such as those used for adsorbing TGFβ, for example, are also suitable and are described in EP-A 0,616,814 and EP-A 0,567,391, as well as the synthetic bone matrices according to WO 91/18558. Materials commonly used when implanting bone substitutes or other therapeuticaily active substances are also suitable as carriers for the compounds of formula (I). Such carriers are also based on, e.g., calcium sulfate, tricalcium phosphate, hydroxyapatite and its biodegradable derivatives, and polyanhydrides. Apart from these biodegradable carriers, those carriers are also suitable which are not biodegradable but are biocompatible. For example, these carriers are sintered -hydroxyapatite, bioglass, aluminates or other ceramic materials (e.g., calcium aluminate phosphate). Preferably, these materials are used in combination with said biodegradable materials, such as, in particular, polylactic acid, hydroxyapatite, collagen, or tricalcium phosphate. Other non- degradable polymers have been described in the US patent 4.164,560, for example. Particularly preferred is the use of carriers which continuously release the compounds of formula (I) at the site of action. Especially suited for this purpose are, e.g., the "slow release pellets" by Innovative Research of America, Toledo, Ohio, USA. Particularly preferred is the use of pellets releasing the compounds of formula (I) over several days, preferably up to 100 days, at a daily dose of 1-10 mg/kg per day. Apart from the compounds mentioned in the examples, and the compounds which may be derived by combining all the meanings of the substituents mentioned in the claims, the following derivatives, as well as their pharmacologically acceptable salts, particularly the hydrochiorides and trifiuoroacetates are preferred in the meaning of the present invention. Index of abbreviations used: Aba = aminobutyric acid Ac = acetyl Ada = (l-amidino-2,5-dihydro-lH-pyrrol-3-yl)alanine Ala = alanine Ava = aminovaleric acid Bn = benzyl Boc = tert-butyloxycarbonyl Bu = butyl Cbz = benzyloxycarbonyl Cha = cyclohexylalanine DBU = l,8-diazabicyclo[5.4.0]undec-7-ene DEBAL-H = diisobutylaluminum hydride DMAP = 4-dimethylaminopyridine DMF = dimethylformamide Et = ethyl Fmoc = 9-fluorenylmethoxycarbonyl Gly = glycine HMDS = hexamethyldisilazane i-Pr = isopropyi Me = methyl NMM = N-methylmorpholine Ph = phenyl Phe = phenylalanine Pro = proline Py = pyridine RT = room temperature Ser = serine t-Bu = tert-butyl TBTU = 2-(lH-benzotriazoi-l-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate TCP - trityl chloride-polystyrene THF = tetrahydrofuran Thr = threonine Troc = 2,2,2-trichloroethoxycarbonyl Tφ = tryptophan Tyr = tyrosine tø = retention time Val = valine In addition the one-letter code for amino acids is used. Within the sense of the present invention the following peptide mimetics are preferred in addition to the compounds mentioned in the examples and compounds that can be derived by combining all meanings of substituents mentioned in the claims in the preferred compounds. Preferred compounds: 1) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylam+ino]-pentanoylamino}-3-(indol-2-yl)-propionic acid 2) 2- { 5-[2- Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3 -yl)-propionylamino]- pentanoylamino } -3-(7-methyl-indol-2-yl)-propionic acid 3) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-benzo[b]thiophen-2-yl-propionic acid 4) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino } -3 -(6-methyl-indol-2-yl)-propionic acid 5) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(6-hydroxy-indol-2-yl)-propionic acid 6) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroI-3-yl)-propionylamino]- pentanoylamino}-3-(3-methyl-indol-2-yl)-propionic acid 7) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyιτol-3-yl)-propionylamino]-pentanoylamino}-3-(3-methyl-benzofuran-2-yl)- propionic acid 8) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(3,4-dimethyl-benzofuran-2-yl)-propionic acid 9) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoyiamino}-3-(3,5-dimethyl-benzofuran-2-yl)- propionic acid 10) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(3,6-dimethyl-benzofuran-2-yl)-propionic acid 11 ) 2- { 5-[2-(2- Amino-3 -hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(5-ethyl-3-methyl-benzofijran-2- yl)-propionic acid 12) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino } -3-hydroxy-3-(3-methyl-benzofuran-2-yl)-propionic acid 13) 2- { 5-[2-(2- Amino-3 -hydroxy-butyrylam o)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pynrol-3-yl)-propionylamino]-pentanoylamino}-3-(3,7-dimethyl-benzofuran-2-yl)- propionic acid 14) 2-{5-[2-Arnino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(7-ethyl-3-methyl-benzofuran-2-yl)-propionic acid 15) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-f3,6-dimethyl-benzofuran-2-yl)- 3-hydroxy-propionic acid 16) 2-(5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-ρyrrol-3-yl)-ρropionyiamino]- pentanoyiamino } -3 -(3 , 5 -dimethyl-benzofuran-2-yl)-3 -hydroxy-propionic acid 17) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(3,4-dimethyl-benzofuran-2-yl)- 3 -hydroxy-propionic acid 18) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(3,7-dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 19) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(7-chloro-3-methyl-benzofuran- 2-yl)-3 -hydroxy-propionic acid 20) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(5-ethyl-3-methyl-benzofuran-2-yl)-3-hydroxy-propionic acid 21) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrroi-3-yl)-propionylamino]-pentanoylamino}-3-(7-ethyl-3-methyl-benzofuran-2- yl)-3 -hydroxy-propionic acid 22) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoyiamino } -3 -furan-2-yl-propionic acid 23) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylaminoj-pentanoylamino}-3-furan-2-yl-3-hydroxy-propionic acid 24) { 5 -[2- Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrro 1-3 -yl)-propionylamino]- pentanoyiamino }-thiophen-2-yl-acetic acid 25) 2-{ 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino } -3 -thiophen-2-yl-propionic acid 26) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-proρionvlamino]- pentanoylamino } -3-(pyrrol-2-yl)-propionic acid 27) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(5-methyl-thiophen-2-yl)- propionic acid 28) 2-{5-[2-j mino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-hydroxy-3-(5-methyl-thiophen-2-yl)-propionic acid 29) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(5-ethyl-thiophen-2-yl)-propionic acid 30) 2- { 5-[2- Amino-3 -( 1 -carbamimidoyl-2,5 -dihydro-pyrrol-3 -yl)-propionyiamino]- pentanoylamino } -3-(5-propyl-thiophen-2-yl)-propionic acid 31) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dthydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(5-hydroxymethyl-furan-2-yl)- propionic acid 32) 5-(2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylaminoj- pentanoylamino } -2-carboxy-ethyl)-2-methyl-furan-3 -carboxylic acid 33) 5-(2-{ 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-2-carboxy-ethyl)-2-ethyl-furan-3- carboxylic acid 34) 5-(2-( 5-[2-Amino-3-(l -carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-2-carboxy-ethyl)-2-methyl-pyrrole-3-carboxylic acid ethyl ester 35) 5-(2- { 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-2-carboxy-ethyl)-2-propyl-furan-3- carboxylic acid 36) 3-(5-Acetylimino-4,5-dihydro-thiophen-2-yl)-2-{5-[2-Amino-3-(l-carbamimidoyl- 2,5-dihydro-pyrrol-3-yl)-propionylamino]-pentanoyiamino} -3 -hydroxy-propionic acid 37) 5-(2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3 -yl)-propionylamino]-pentanoylamino } -2-carboxy-ethyl)-2-isobutyl-furan- 3 -carboxylic acid 38) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoyl amino } -3 -cyclopent- 1 -enyl-propionic acid 39) 2-{5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-hydroxy-3-thiophen-2-yl- propionic acid 40) {5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino } -(3-methyl-benzo[b]thiophen-7-yl)-acetic acid 41) {5-[2-(2-Amino-3-hydroxy-butyryiamino)-3-(l-carbamimidoyl-2,5-dihydro-pyrrol- 3-yl)-propionyiamino]-pentanoylamino } -phenyl-acetic acid 42) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic acid 43) { 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro-pyrrol- 3-yl)-propionylamino]-pentanoylamino } -(4-hydroxy-phenyl)-acetic acid 44) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoyiamino } -3-phenyl-butyric acid 45) 2-{5-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( l-carbamimidoyi-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-3-(3,4-bis-benzyloxy-phenyi)-3- hydroxy-propionic acid 46) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoyiamino } -3-hydroxy-succinic acid 47) 2-({ 5-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-pentanoylamino}-carboxy-methyl)-benzoic acid 48) 5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino}-(3-oxo-2,3-dihydro-isoxazol-5-yl)-acetic acid 49) { 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamirnidoyl-2.5-dihydro-pyrrol- 3-yl)-propionylamino]-pentanoylamino } -cyclohexyi-acetic acid 50) {5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino]- pentanoylamino } -cyclohexa- 1 ,4-dienyl-acetic acid 51) { 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro-pyrrol- 3 -yl)-propionylamino]-pentanoylamino} -cyclohexa- 1 ,5-dienyi-acetic acid 52) 2- { 5-[2-Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrro 1-3 -yl)-propionylamino]- pentanoyiamino } -3-hydroxy-3-pyridin-3-yl-propionic acid 53) 2-{5-[2-(2-Amino-3-hydroxy-butyrylam^no)-3-(l-carbamimidoyl-2,5-dihydro- pyrroi-3-yl)-propionylamino]-pentanoylamino}-3-hydroxy-3-pyridin-4-yl-propionic acid 54) 4-({5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino } -carboxy-methyl)-2-hydroxy-benzoic acid 55) 4-( { 5-[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pyrroi-3-yl)-propionyiamino j-pentanoylamino } -carboxy-methyl)-benzoic acid 56) 2-{5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoylamino } -3-phenylsulfanyl-butyric acid 57) {5-[2-(2-Amino-3-hydroxy-butyryiamino)-3-(l-carbamimidoyl-2,5-dihydro-pyrrol- 3-yl)-propionylamino]-pentanoylamino)-(tetrazol-5-yl)-acetic acid 58) {5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- pentanoyiamino } -(indol-3 -yl)-acetic acid 59) { 5-[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol- 3-yl)-propionylamino]-pentanoyiamino}-(3,4-dihydroxy-phenyi)-acetic acid 60) { 5-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino]- pentanoylamino } -(3 , 5 -dihydroxy-phenyl)-acetic acid 61) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino]- butyrylamino}-3-(indol-2-yi)-propionic acid 62) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(7-methyl-indol-2-yl)-propionic acid 63) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino}-3-benzo[b]thiophen-2-yl-propionic acid 64) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l -carbamimidoyl-2, 5-dihydro- pyrroi-3-yl)-propionylamino]-butyrylamino}-3-(6-methyi-indol-2-yl)-propionic acid 65) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylaminoj- butyrylamino } -3 -(6-hydroxy-indol-2-yl)-propionic acid 66) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(3-methyl-indol-2-yl)-propionic acid 67) 2-{4-[2-Amino-3-(l-caroarnimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino}-3-(3-methyl-benzofuran-2-yl)-propionic acid 68) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyryiamino } -3-(3 ,4-dimethyl-benzofuran-2-yl)- propionic acid 69) 2- (4-[2- Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyττol-3 -yl)-propionylamino]- butyrylamino}-3-(3,5-dimethyl-benzofuran-2-yl)-propionic acid 70) 2-{4-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-butyrylamino}-3-(3,6-dimethyl-benzofuran-2-yl)- propionic acid 71) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyryiamino }-3-(5-ethyl-3-methyl-benzofuran-2-yl)-propionic acid 72) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-butyryiamino}-3-hydroxy-3-(3-methyl-benzofuran-2- yl)-propionic acid 73) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyryiamino }-3-(3,7-dimethyl-benzoruran-2-yl)-propionic acid 74) 2-{4-[2-(2-Amino-3-hydroxy-butyτylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyτrol-3-yl)-propionylamino]-butyrylamino}-3-(7-ethyl-3-methyl-benzofuran-2-yl)- propionic acid 75) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrτol-3-yl)-propionylamino]- butyryiamino } -3-(3,6-dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 76) 2-{4-[2-(2-Amino-3-hydroxy-butyτylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(3,5-dimethyl-benzofuran-2-yl)-3- hydroxy-propionic acid 77) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -3-(3,4-dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 78) 2-{4-[2-(2-Amino-3-hydroxy-butyτylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(3,7-dimethyl-benzofuran-2-yl)-3- hydroxy-propionic acid 79) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyιτol-3-yl)-propionylamino]- butyryiamino}-3-(7-chloro-3-methyl-benzofuran-2-yl)-3-hydroxy-propionic acid 80) 2- {4-[2-(2- Amino-3 -hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-butyrylamino}-3-(5-ethyl-3-methyl-benzofuran-2-yl)- 3-hydroxy-propionic acid 81) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino ) -3 -(7-ethyl-3 -methyl-benzoruran-2-y 1 ) - 3 -hydroxy-propionic acid 82) 2-{4-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino } -3-furan-2-yl-propionic acid 83) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -3-furan-2-yl-3-hydroxy-propionic acid 84) { 4-[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrroi- 3-yl)-propionylamino]-butyrylamino } -thiophen-2-yl-acetic acid 85) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -3-thiophen-2-yl-propionic acid 86) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(pyrrol-2-yl)-propionic acid 87) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- butyrylamino}-3-(5-methyl-thiophen-2-yl)-propionic acid 88) 2-(4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyryiamino } -3 -hydroxy-3 -( 5-methyl-thiophen-2- yl)-propionic acid 89) 2-(4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -3-(5-ethyl-thiophen-2-yl)-propionic acid 90) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-(5-propyl-thiophen-2-yl)-propionic acid 91) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino}-3-(5-hydroxymethyl-furan-2-yl)-propionic acid 92) 5-(2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-2-carboxy-ethyl)-2-methyl-furan-3- carboxylic acid 93) 5-(2-{4-{2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -2-carboxy-ethyl)-2-ethyl-furan-3 -carboxylic acid 94) 5-(2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyiylamino}-2-carboxy-ethyl)-2-methyl-pyrrole-3- carboxylic acid ethyl ester .95) 5-(2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -2-carboxy-ethyl)-2-propyl-furan-3 -carboxylic acid 96) 3-(5-Acetyiimino-4,5-dihydro-thiophen-2-yl)-2-{4-[2-(2-amino-3-hydroxy- butyrylamiπo)-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3 -yl)-propionylamino]- butyrylamino}-3-hydroxy-propionic acid 97) 5-(2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -2-carboxy-ethyl)-2-isobutyl-furan-3 -carboxylic acid 98) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino } -3 -cyclopent- 1 -enyl-propionic acid 99) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyryiamino } -3-hydroxy-3-thiophen-2-yl-propionic acid 100) {4-[2-(2- Amino-3 -hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol- 3-yl)-propionylamino]-butyryiamino}-(3-methyl-benzo[b]thiophen-7-yl)-acetic acid 101) {4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino}-phenyl-acetic acid 102) 2- { 4-[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino } -3 -(3 ,4-dihydroxy-phenyl)-3-hydroxy- propionic acid 103 ) { 4-[2- Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3 -yl)-propionylamino]- butyrylamino } -(4-hydroxy-phenyl)-acetic acid 104) 2- { 4-[2-(2- Amino-3 -hydroxy-butyry lamino)-3 -( 1 -c arbamimidoyl-2.5 -dihydro- pyrroi-3-yl)-propionylamino]-butyrylamino}-3-phenyl-butyric acid 105) 2-{4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- butyryiamino}-3-(3,4-bis-benzyloxy-phenyi)-3-hydroxy-propionic acid 106) 2- { 4-[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino } -3-hydroxy-succinic acid 107) 2-({4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -carboxy-methyl)-benzoic acid 108) 5-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyi-2,5-dihydro-pyrrol- 3-yl)-propionyiamino]-butyrylamino}-(3-oxo-2,3-dihydro-isoxazol-5-yl)-acetic acid 109) {4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino}-cyclohexyl-acetic acid 110) {4-[2-(2-Amino-3-hydroxy-butyryiamino)-3-(l-carbamimidoyl-2,5-dihydro-pyrrol- 3-yl)-propionylamino]-butyrylamino}-cyclohexa-l,4-dienyl-acetic acid 111) {4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -cyclohexa- 1 ,5-dienyl-acetic acid 112) 2-{4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3 -yl)-propionylamino] -butyrylamino } -3 -hydroxy-3 - pyridin-3 -yl-propionic acid 113) 2-(4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -3-hydroxy-3-pyridin-4-yl-propionic acid 1 14) 4-({4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-butyrylamino}-carboxy-methyl)-2-hydroxy-benzoic acid 1 15) 4-({4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -carboxy-methyl)-benzoic acid 1 16) 2-{4-[2-(2-Amino-3-hydroxy-butyryiamino)-3-(l-carbamimidoyI-2,5-dihydro- pyrrol-3-yl)-propionylamino]-butyrylamino}-3-phenylsulfanyl-butyric acid 117) {4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- butyrylamino } -(tetrazol-5-yl)-acetic acid 118) (4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l -carbamimidoyl-2, 5-dihydro-pyrrol- 3-yl)-propionyiamino]-butyryiamino}-(indol-3-yl)-acetic acid 1 19) {4-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- butyryiamino } -(3,4-dihydroxy-phenyl)-acetic acid 120) (4-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro-pyrrol- 3-yl)-propionylamino]-butyrylamino}-(3,5-dihydroxy-phenyl)-acetic acid 121) 2-{3-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-propionylamino } -3-(indol-2-yl)-propionic acid 122) 2- { 6-[2- Amino-3-( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3 -yl)-propionylamino]- hexanoyiamino}-3-(7-methyl-indol-2-yl)-propionic acid 123) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino } -propionylamino)-3- benzo[b]thiophen-2-yl-propionic acid 124) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyιτol-3-yl)-propionylamino]- propionylamino } -3 -(6-methyl-indol-2-yl)-propionic acid 125) 2-{6-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-hexanoylamino}-3-(6-hydroxy-indol-2-yl)-propionic acid 126) 2-(2-{2-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- 3-hydroxy-propionylamino}-propionylamino)-3-(3-methyl-indol-2-yl)-propionic acid 127) 2- { 3 -[2-(2- Amino-3 -hydroxy-butyrylamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-3-(3-methyl-benzofuran-2-yl)- propionic acid 128) 2-(2-{2-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- 3-hydroxy-propionylamino}-propionylamino)-3-(3,4-dimethyl-benzofuran-2-yl)- propionic acid 129) 2- { 6-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-hexanoylamino } -3-(3 , 5 -dimethyl-benzofuran-2-yl)- propionic acid 130) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino}-propionylamino)-3-(5- ethyl-3-methyl-benzofuran-2-yl)-propionic acid 131) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- propionylamino}-3-hydroxy-3-(3-methyl-benzofuran-2-yl)-propionic acid 132) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino}-propionylamino)-3-(3,7- dimethyl-benzofuran-2-yl)-propionic acid 133) 2-{6-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- hexanoylamino}-3-(7-ethyl-3-methyl-benzofuran-2-yl)-propionic acid 134) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-3-hydroxy-propionyiamino}-propionylamino)-3-(3,6- dimethyl-benzofuran-2-yl)-3 -hydroxy-propionic acid 135) 2- { 3 -[2- Amino-3 -( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3-yl)-propionylamino]- propionylamino}-3-(3,5-dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 136) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino}-propionylamino)-3-(3,4- dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 137) 2- { 6-[2- Amino-3-( 1 -carbamimidoyl-2, 5 -dihydro-pyrrol-3 -yl)-propionylamino]- hexanoylamino } -3-(3 ,7-dimethyl-benzofuran-2-yl)-3-hydroxy-propionic acid 138) 2-(2-(2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyττol-3-yl)-propionylamino]-3-hydroxy-propionyiamino}-propionylamino)-3-(7- chloro-3-methyl-benzofuran-2-yl)-3-hydroxy-propionic acid 139) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino } -3-(5-ethyl-3-methyl-benzofuran-2-yl)-3-hydroxy-propionic acid 140) 2-{6-[2-(2-Amino-3-hydroxy-butyryiamino)-3-(l -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-hexanoylamino}-3-(7-ethyl-3-methyl-benzofuran-2- yl)-3 -hydroxy-propionic acid 141) 2- { 6-[2- Amino-3 -( 1 -carbamimidoyl-2,5 -dihydro-pyrrol-3-yl)-propionylamino]- hexanoylamino }-3-furan-2-yl-propionic acid 142) 2-{3-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-3-furan-2-yl-3-hydroxy-propionic acid 143) {3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino }-thiophen-2-yl-acetic acid 144) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino}-propionylamino)-3- thiophen-2-yl-propionic acid 145) 2-{6-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- hexanoylamino }-3-(pyrrol-2-yl)-propionic acid 146) 2-{3-[2-(2-Amino-3-hydroxy-butytylamino)-3-( 1 -carbamimidoyi-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-3-(5-methyl-thiophen-2-yl)- propionic acid 147) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionyiamino } -propionylamino)-3-(5- ethyl-thiophen-2-yl)-propionic acid 148) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino]- propionylamino}-3-(5-propyl-thiophen-2-yl)-propionic acid 149) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-3-hydroxy-propionylamino}-propionylamino)-3-(5- hydroxymethyl-furan-2-yl)-propionic acid 150) 5-(2-(6-[2-Amino-3-(l-carbaminτidoyl-2,5-dihydro-pyrrol-3-yl)-propionylarnino]- hexanoylamino } -2-carboxy-ethyl)-2-methyl-furan-3 -carboxylic acid 151) 5-(2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5- dihydro-pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino } - propionylamino)-2-carboxy-ethyl)-2-ethyl-ruran-3-carboxyiic acid 152) 5-(2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino}-2-carboxy-ethyl)-2-methyl-pyrrole-3-carboxylic acid ethyl ester 153) 5-(2-{6-[2-(2-Amino-3-hydroxy-butyrylamino)-3-< ' 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-hexanoylamino}-2-carboxy-ethyl)-2-propyl-furan-3- carboxylic acid 154) 5-(2-{ 3-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-2-carboxy-ethyl)-2-isobutyl-furan- 3 -carboxylic acid 155) (2-{2-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrτol-3-yl)-propionylamino]-3- hydroxy-propionyiamino}-propionyiamino)-3-cyciopem- l-enyi-propionic acid 156) 2- { 3-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-3-hydroxy-3-thiophen-2-yl- propionic acid 157) 2-{6-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- hexanoylamino}-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic acid 158) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino}-3-phenyl-butyric acid 159) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-3-hydroxy-propionylamino}-propionylamino)-3-(3,4- bis-benzyloxy-phenyl)-3 -hydroxy-propionic acid 160) 2-{6-[2-Amino-3-(l-carbamirnidoyl-2,5-dihydro-pyrroi-3-yl)-propionyiamino]- hexanoylamino) -3-hydroxy-succinic acid 161) {3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino } -cyclohexa- 1 ,4-dienyl-acetic acid 162) 2- { 3-[2- Amino-3 -( 1 -carbamimidoyl-2, 5-dihydro-pyrrol-3 -yl)-propionylamino]- propionylamino } -3-hydroxy-3-pyridin-3-yl-propionic acid 163) 4-({6-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino - hexanoyiamino } -carboxy-methyl)-2-hydroxy-benzoic acid 164) 2-{3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino)-3-phenyisulfanyl-butyric acid 165) {6-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- hexanoylamino} -(indol-3-yl)-acetic acid 166) {3-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrroi-3-yl)-propionylamino]- propionylamino }-(3,5-dihydroxy-phenyl)-acetic acid 167) (2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionyiamino]-propionylamino}-propionylamino)-3-(6-hydroxy- indol-2-yl)-propionic acid 168) (2-{2-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionyiamino]- propionyiamino}-propionylamino)-3-(3,6-dimethyl-benzofuran-2-yl)-propionic acid 169) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino} -propionylamino )-3-(3,4-dimethyl- benzofuran-2-yl)-3-hydroxy-propionic acid 170) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylaminoj-propionylamino}-propionylamino)-3-(7-ethyl-3- methyl-benzofuran-2-yl)-3 -hydroxy-propionic acid 171) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyryiamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino } -propionylamino)-3 -thiophen-2-yl- propionic acid 172) 2-(2-{2-[2-(2-Amino-3-hydroxy-bi'tyrylamino)-3 -( 1 -carbamimidoyl-2,5-dihydro- pyπOl-3-yl)-propionylamino]-propionylamino}-propionylamino)-3-(5-methyl- thiophen-2-yl)-propionic acid 173) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-propionylamino)-3-(5- hydroxymethyl-furan-2-yl)-propionic acid 174) 3 -(5- Acetylimino-4, 5-dihydro-thiophen-2-yl)-(2- { 2-[2- Amino-3 -( 1 -carbamimidoyl- 2,5-dihydro-pyrrol-3-yl)-propionyiamino]-propionylamino } -propionylamino)- 3- hydroxy-propionic acid 175) (2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino } -propionylamino)-phenyl-acetic acid 176) (2-{2-[2-Amino-3-(l-carbamimidoyl-2,5-dihydro-pyrrol-3-yl)-propionylamino]- propionylamino }-propionylamino)-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic acid 177) 2-(2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionyiamino}-propionylamino)-3-(3,4-bis- benzy loxy-pheny l)-3 -hydroxy-propionic acid 178) 2-((2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-propionylamino)-carboxy-methyl)- benzoic acid 179) 2-(2- { 2-[2-(2- Amino-3 -hydroxy-butyry lamino)-3 -( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-propionyiamino)-3-hydroxy-3- pyridin-4-yl-propionic acid 180) (2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-(l-carbamimidoyl-2,5-dihydro- pyrrol-3-yl)-propionylamino]-propionylamino}-propionylamino)-(tetrazol-5-yl)- acetic acid 181) (2-{2-[2-(2-Amino-3-hydroxy-butyrylamino)-3-( 1 -carbamimidoyl-2, 5 -dihydro- pyrrol-3-yl)-propionylamino]-propionyiamino}-propionylamino)-(3,4-dihydroxy- phenyl)-acetic acid The following examples exemplify variants for the synthesis of the compounds of the invention. The structure of the compounds was obtained by Η-, ' " 'C-NMR-s spectroscopy and optionally by mass-spectroscopy. The purity of the substances was obtained by C, H, N analyses and by chromatography. Example 1 (±)-3-(2-tert.-Butoxycarbonyl-amino-2-hydroxycarbonyl)-ethyl-2,5-dihydropyrrole- l-(N,N'-di-tent-butoxycarbonyi) carboxamidine [Boc-Ada(Boc) 2 OH] a) 4-Oxo-pyrrolidine-l,3-dicarboxylic acid 1-tert. butylester 3-ethylester (J. Cooper et al. J. Chem.Soc.Perkin Trans. 1, 1993, 1313-1318) To a refluxing suspension of 1.58 g (66 mmol) sodium hydride in 100 ml THF was added dropwise a solution of 12.79 g (60 mmol) N-tert-butyloxycarbonyi-glycine ethyl ester and 7.15 g (66 mmol) ethyl acrylate in 100 ml THF. After the addition was complete the mixture was heated to reflux for additional 2 h. The clear solution was cooled to room temperature, poured on 100 ml ether/ 100 ml water and acidified under vigorous stirring with IN hydrochloric acid against methyl orange. The layers were separated and the aqueous layer was extracted three times with ether. The combined organic layers were washed with sat. sodium bicarbonate and brine, dried over MgSO 4 and evaporated. Short-path distillation of the residue gave 10.92 g (71 %) 4-oxo-pyrrolidine-l,3- dicarboxylic acid 1-tert. butylester 3-ethyiester as a colorless oil, b.p. 1 19 - 122 °C (0.2 mbar), which solidified on prolonged standing in the freezer GC/MS (HP 5890 II HP 5972; column: HP 5, 30 m x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min; then with 20 °C/min to 250 °C) t R = 9.68 min m/z [%] = 185 (2), 130 (10), 112 (18), 85 (6), 57 (100). b) 4-Hydroxy-pyrroiidine-l,3-dicarboxylic acid l-terr.-butylester 3-ethylester To a solution of 5.15 g (20 mmol) 4-oxo-pyrrolidine- l,3-dicarboxylic acid 1-tert. butylester 3-ethylester in 30 ml methanol was added 1.88 g (30 mmol) sodium cyanoborohydride and a small amount of methylorange. With stirring the pH was adjusted to 3 by dropwise addition of IN hydrochloric acid (color change from yellow to orange). After no more acid was consumed the mixture was stirred for one hour. The solvent was evaporated in vacuo and the residue was partitioned between ethyl acetate and water. The organic layer was washed twice with water, then with brine, dried over magnesium sulfate and evaporated. The residual yellow oil was used in the next step without any further purification. GC/MS (HP 5890 II/HP 5972; column: HP 5, 30 m x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min; then with 20 °C/min to 250 °C;) tR = 12.44 min (no separation of diastereomers) m/z [%] = 259 (M * ,0.3), 241 (0.7), 202 (5), 186 (7), 158 ( 10), 112 (14), 68 (31), 57 (100). c) 4-Benzoyioxy-pyrrolidine-l,3-dicarboxylic acid l-fert.-butylester 3- ethylester To an ice-cooled solution of the crude 4-hydroxy-pyrrolidine-l,3-dicarboxylic acid 1- ter/. -butylester 3-ethylester from the reduction described above and 244 mg (2 mmol) DMAP in 40 ml pyridine were added dropwise 3.51 g (25 mmol) benzoyl chloride. After the addition was complete, the ice bath was removed and the mixture was stirred at room temperature for 2 h. The mixture was diluted with ethyl acetate an poured on ice. The organic layer was separated, washed with water, sat. CuSOi. water and brine, dried over MgSO and evaporated. The residual yellow oil was used in the next step without further purification. GC/MS (HP 5890 II/HP 5972; column: HP 5, 30 x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min; then with 20 °C/min to 250 °C) t R = 17.28 and 17.38 min (1 : 1-mixture of cis/trans-isomers m/z [%] = 318 (0.1), 290 (5), 262 (2), 241.(2), 185 (29), 141 (10), 1 12 (23), 105 (53), 77 (27), 68 (100), 57 (97). d) 2,5-Dihydro-pyrrole-l,3-dicarboxylic acid 1-tert-butylester 3-ethyl ester To a solution of the crude 4-benzoyloxy-pyrrolidine- 1 , 3 -dicarboxylic acid 1 -ten. - butylester 3-ethylester from the benzoylation described above in 75 ml dry toluene was added 4.11 g (27 mmol) DBU. The dark, heterogeneous mixture was stirred at room temperature for 16 h. After this time no starting material was detectable by TLC and GC analysis. The mixture was filtered through a short column of silica (elution with petrolether/ethyl acetate 1 . 1) and evaporated. Bulb-to-bulb distillation of the residual slightly yellow oil gave 4.16 g (86 %) 2,5-dihydro-pyrroie-l,3-dicarboxyiic acid 1-tert. - butylester 3-ethyl ester as a colorless oil b.p. 110 °C/0.2 mbar, which slowly solidified to a waxy mass on standing in the freezer. GC/MS (HP 5890 II HP 5972; column: HP 5, 30 m x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min: then with 20 °C/min to 250 °C) t R = 1 1.94 min m/z [%] = 241 (M\ 1.4), 196 (0.4), 185 (1 1), 168 (1 1 ), 140 ( 14), 1 12 (17), 68 (24), 57 (100). Η-NMR (CDCU, 300 MHz) d = 1.27 (t, J = 7.1 Hz, 3H, OCH 2 CH 3 ), 1.43, 1.44 [2s, 9H, C(CH 3 ) 3 ]\ 4.25 (d, J = 7.1 Hz, 2H, OCΪLCH ? ), 4.15 - 4.27 (br. m, 4H, 2-H, 5-H), 6.66 - 6.71 (m, 1H, 4-H) ppm. "Double set of signals due to hindered rotation. ,3 C-NMR (CDCU, 75 MHz) d = 14.16, 14.20 (q, -CH 2 -CH ? )*, 28.45 [q, -C(CH 3 ) ? ], 51.76. 51.99. 53.62. 53.84 (4t, C-2, C-5)*, 60.69 (t, -CH 2 -CH 3 ), 79.84 [s, -C(CH 3 ) ? ], 132.29 (s, C-3), 136.44, 136.55 (2d, C-4)*, 153.86, 154.08 (2s, -NCOO-)*, 162.75 (s, COOEt) ppm. e) 3-Hydroxymethyl-2,5-dihydro-pyrrole-l-carbox iic acid tert. -butylester To a solution of 5.43 g (22.5 mmol) 2,5-dihydro-pyrrole- 1 ,3-dicarboxylic acid 1-tert. - butylester 3-ethyl ester in 50 ml THF, cooled to - 78 °C was dropwise added 50 ml of a IN DIBAL-H solution in hexane. The mixture was allowed to warm to room temperature overnight. As TLC analysis indicated complete consump on of starting material, the mixture was cooled in an ice bath and 1.90 g water were cautiously added, followed by 1.90 g 15 % aqueous NaOH and 5.70 g water. The white precipitate was filtered off, washed thoroughly with ether and the combined filtrates were evaporated. Bulb-to-bulb distillation of the residual pale yellow oil gave 4.13 g (93 %) 3- hydroxymethyl-2,5-dihydro-pyrroie-l -carboxylic acid tert. -butylester as a colorless oil, b.p. 130 °C (0.2 mbar). GC/MS (HP 5890 II/HP 5972; column: HP 5, 30 x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min; then with 20 °C/min to 250 °C) t R = 11.34 min m z [%] = 199 (M , 1), 143 (10), 142 (13), 126 (13), 112 (12), 80 (10), 68 (45), 57 (100). Η-NMR (CDC1,, 300 MHz) d = 1 44 (s, 9H, t-Bu), 4.09 (br. m. 4H, 2-H, 4-H), 4. 18 (br. s. 2H. CH 2 OH), 5.63 (br. d, 1H, 4-H) ppm. ,3 C-NMR (CDClj, 75 MHz) d = 28.5 [q, C(CH } ) 3 ], 52.8, 53.0, 53.2, 53.3 (4t, C-2, C-5)', 57.7, 59.8 (2d, CH 2 OH), 79.5 [s, C(CH 3 ) 3 ], 120.0, 120.3 (2d, C-4), 139.6 (s, C-3), 154.4 (s, QOOtBu) ppm. Double set of signals due to hindered rotation 0 3-Acetoxymethyl-2,5-dihydro-pyrrole-l-carboxviic acid tert. -butylester To an ice-cooled solution of 4.13 g (20.7 mmol) 3-hydroxymethyl-2,5-dihydro-pyrrole- 1-carboxyiic acid tert. -butylester and 244 mg (2 mmol) DMAP in 50 ml pyridine was added 3.06 g (30 mmol) acetic anhydride. The mixture was stirred for 30 min at 0 °C, then for additional 60 min at room temperature. The mixture was poured on ice and extracted twice with ether. The combined organic layers were evaporated in vacuo, dissolved in ether, washed with sat. CuSO 4 , water and brine and dried over MgSO 4 . Evaporation and bulb-to-bulb distillation gave 4.82 g (97 %) 3-acetoxymethyl-2,5- dihydro-pyrrole-1 -carboxylic acid tert. -butylester as a colorless oil, b.p. 105 °C (0.2 mbar). GC/MS (HP 5890 II/HP 5972; column: HP 5, 30 m x 25 mm x 0.25 μm film thickness, carrier gas: helium; temperature gradient: 50 °C, 3 min: then with 20 °C/min to 250 °C) t R = 1 1.87 min m/z [%] - 241 (M\ 0.2), 226 (0.1), 185 (5), 166 (5), 125 (18), 108 (3), 81 (13), 80 (23), 57 (100). 'H-NMR (CDC , 300 MHz) d = 1.43, 1.44 [2s, 9H C(CH3) 3 ]*, 2.04, 2.06 (2s, 3H, OOCCH 3 )*, 4.05 - 4.12 (br. m, 4H, 2-H, 5-H), 4.61 (br. d, J= 5.7 Hz, 2H, CH 2 O), 5.66 - 5.73 (br. m, 1H, 4-H) ppm. "C-NMR (CDClj, 75 MHz) d = 20.7 (q, OOCCH 3 ), 28.4 [q, C(ςH 3 ) 3 ], 53.0, 53.2, 53.3 (3t, 2-C, 5-C)*, 60.8 (t, CH 2 OAc), 79.5 [s, (CH,)3], 123.4, 123.8 (2d, C-4)*, 134.5, 134,6 (2s, C-3), 154.1 (s, NCOO), 170.5 (s, OOCCH,) ppm. g) 3-Acetoxymethyl-2,5-dihydro-pyrroIe-l-(N,N'-di-fert.-butoxycarbonyl) carboxamidine To an ice-cooled solution of 1.21 g (5 mmol) 3-acetoxymethyl-2,5-dihydro-pyrrole-l- carboxylic acid tert. -butylester from example 3f) in 10 ml dry dioxane was added 10 ml 4N hydrogen chloride in dioxane. The mixture was stirred at 0 °C for 16 h. The mixture was evaporated to dryness without heating and then evacuated in high vacuum for several hours. The dark residue was suspended in 20 ml dry acetonitrile and 776 mg (6 mmol) ethyl diisopropylamine, followed by 1.71 g (5.5 mmol) N,N ' -bis-tert.- butyloxycarbonyl-lH-pyrazole-1 -carboxamidine were added. The mixture was stirred for 2 h at room temperature and then evaporated and purified by flash chromatography (petrol ether/ethyl acetate 3:1 to 2:1) to yield 1.87 g (97 %) of 3-acetoxymethyl-2,5- dihydro-pyrroie-l-(N,N'-di-tert.-butoxycarbonyi) carboxamidine as a colorless, sticky solid. Η-NMR (CDClj, 300 MHz) d = 1.45 (s, 18H, 2 t-Bu), 2.03 (s, 3H OAc), 4.38 (br. m, 4H, 2-H, 5-H), 4.61 (s, 2H, CiLOAc), 5.72 (br. m, 1H, 4-H), 10.22 (br. s, 1H, NH) ppm. I3 C-NMR (CDCl ? , 75 MHz) d = 20.4 (q, OOCCH 3 ), 27.7, 27.9 [2q, C(CJHj) 3 ], 55.0 (br. t. C-2, C-5), 60.2 (t, CH 2 OAc), 79.3, 81.8 [2 br. s, C(CH 3 )3], 122.4 (d, C-4), 133.5 (s, C-3), 150 (br. s, NCOO), 153.9 (s, NC=N), 162 (br. s, NCOO), 170.2 (s, OOQH 2 CH 3 ) ppm. h) 3-(2-Benzhydrilideneamino-2-ethoxycarbonyl-ethyl)-2,5-dihydropyrrole-l- (N,N'-di-ter£-butoxycarboπyl) carboxamidine To a solution of lithium hexamethyldisilazide, freshly prepared at 0 °C from 710 mg (4.4 mmol) hexamethyldisilazane in 8 ml THF and 1.92 g (4.4 mmol) n-Butyl-lithium, (2.29 mmol/g in hexanes) and cooled to - 78 °C was added a solution of 1.069 g (4 mmol) ethyl N-(diphenylmethylene)-glycinate in 8 ml THF. The orange enolate solution was stirred for 30 min at -78 °C, then a solution of 1.039 g (3.7 mmol) 3-acetoxymethyl-2,5- dihydro-pyrrole-l-(N,N'-di-tert.-butoxycarbonyl) carboxamidine and 426 mg (0.4 mmol) Pd(PPh?) 4 in 12 ml THF was added dropwise. The reaction mixture was allowed to warm to room temperature over 2 h and was stirred for additional 12 h. The mixture was diluted with ether and quenched by addition of sat. NaHCO?. The organic layer was washed with sat. NaHCO 3 and brine, dried over MgSO 4 and evaporated. Purification by flash chromatography (ethyl acetate/petrol ether 1 :5 + 1% triethylamine) gave 1.03 g (47 %) of 3-(2-benzhydrylideneamino-2-ethoxycarbonyi-ethyl)-2,5-dihydropyrrole-l-(N,N'- di-terf.-butoxycarbonyl) carboxamidine as a colorless, amorphous solid. 'H-NMR (CDClj, 300 MHz) d - 1.23 (t, J = 7.1 Hz, 3H, OCH2CH 3 ), 1.46 [br. s, 18H. C(CH } ) 3 ], 2.68 (br. m, 2H, 3- CH 2 -), 3.96 (br. m, 1H, CH-N), 4.15 (q, J= 7.1 Hz, 2H, OCPLCHj), 4.16 - 4.29 (br. m, 4H, 2-H, 5-H), 5.41 (br. m, 1H, 4-H), 7.07 - 7.60 (m, 10 H, Ar-H) ppm. d = 13.9 (q, OCHzCHj), 28.0 [q, C(CH 3 ) 3 ], 32.5 (t, 3-CH 2 ), 55.2, 56.9 (2t, C-2, C-5), 60.9 (t, OCH 2 CH ? ), 63.6 (d, CH-NH 2 ), 79, 81.6 [2 br. s, £(CH 3 ) 3 ], 120.7 (d, C-4), 127.5, 127.8, 128.4, 128.5, 128.6, 130.2 (6d, Ar-CH), 134.8 (s, C-3), 135.8, 139.1 (2s, Ar-C), 150 (br. s, NCOO), 153.7 (s, NC=N), 162 (br. s, NCOO), 170.7 (s, N=CPh 2 ), 171.2 (s, OOCH 2 CH 3 ) ppm. i) 3-(2-Amino-2-ethoxycarbonyi-ethyI)-2,5-dihydropyrroie-l-(N,N'-di-tert- butoxycarbonyi) carboxamidine To a solution of 118 mg (0.2 mmol) 3-(2-benzhydrilideneamino-2-ethoxycarbonyl-ethyl)- 2,5-dihydropyrroie-l-(N,N'-di-tert.-butoxycarbonyl) carboxamidine in 2 ml THF was added 1 ml IN hydrochloric acid. The mixture was stirred at room temperature for 30 min. Water (5 ml) was added, the aqueous layer was separated and washed twice with ether. The aqueous layer was brought to pH = 8.5 by addition of IN NaHCO 3 and was extracted five times with ether. The combined ether layers were washed with brine, dried over MgSO 4 and evaporated. The residue was purified by flash chromatography (chloroform/ ' methanol 20: 1) to yield 79 mg (93 %) 3-(2-amino-2-ethoxycarbonyl-ethyl)- 2,5-dihydropyrrole-l-(N,N ' -di-tert.-butoxycarbonyl) carboxamidine as a colorless oil. d - 1.22 (t, J= 7.1 Hz, 3H, OCH 2 CH 3 ), 1.45 [s, 18H, C(CH 3 ) 3 ], 2.33 (dd, 2 J= 16.6 Hz, V- 8.1 Hz, 1H, CftHkCHNHj), 2.54 (dd, 2 J= 16.6 Hz. V= 5.3 Hz, 1H, CH.HbCHNHϊ), 3 -5 (dd, 3 J= 8.1, 5.3 Hz, 1H, CH.H b CHNH 2 ), 4.13 (q, J= 7.1 Hz, 2H, OCHzCH,), 4.33 (br. m, 4H, 2-H, 5-H), 5.53 (br. m, 1H, 4-H) ppm "C-N R (CDCK, 75 MHz) d = 13.9 (q, OCH ϊ CHj), 27.9 [q, C(CH 3 ) 3 ], 34.1 (t, 3-CH 2 ), 52.7 (d, CHNH 2 ), 55.3, 56.9 (2d , C-2, C-5), 61.1 (t, OCH 2 CH 3 ), ca 80 [2 br. s. C(CH r ,) : .], 120.7 (d, C-4), 134.6 (s, C-3), 153.8 (s, NC=N), 174.6 (s, OOCH 2 CH 5 ) ppm. j) 3-{2-tert.-Butoxycarbonyl-amino-2-ethoxycarbonyl-ethyl)-2,5- dihydropyrrole-l-(N,N'-di-tert-butoxycarboπyl) carboxamidine To a solution of 79 mg (0.19 mmol) 3-(2-amino-2-ethoxycarbonyl-ethyl)-2,5- dihydropyrrole-l-(N,N'-di-/ert.-butoxycarbonyl) carboxamidine in I ml dry acetonitrile was added 40 mg (0.3 mmol) ethyl diisopropylamine and 65 mg (0.3 mmol) di-tert. -butyl dicarbonate (Boc 2 O) and the mixture was stirred for 16 h at room temperature. The solvent was evaporated and the residue was purified by flash chromatography (petrol ether/ethyl acetate 2:1) to yield 83 mg (76 %) 3-(2-/ert.-butoxycarbonyl-amino-2- ethoxycarbonyl-ethyl)-2,5-dihydropyrrole-l-(N,N'-di-tert.-butoxycarbonyl) carboxamidine as a colorless oil. 'H-NMR (CDClj, 200 MHz) d - 1.22 (t, J = 7.1 Hz, 3H, OCH2CH 3 ), 1.42, 1.47, 1.48 [3 s, 9H each, C(CH 3 ) 3 ], 2.41 - 2.66 (br. m, 2H, 3-CH 2 -), 4.17 (q, J = 7.1 Hz, 2H, OCH2CH), 4.32 (br. m, 4H, 2-H, 5- H), 5.02 (br. m, 1H, CHNH), 5.52 (br. s, 1H, 4-H) ppm. ,3 C-NMR (CDCU, 50 MHz) d = 14.1 (q, OCH 2 CH 3 ), 28.1, 28.3, 28.5 [3q, C(CH 3 ) 3 ], 3 .8 (t, 3-CH 2 ), 48.3 (d, CHNH), 52.0, 55.3 (2t, C-2, C-5), 61.6 (t, OCH 2 CH>), 121.3 (d, C-4), 133.5 (s, C-3), 153.9 (s, N=C-N), 171.8 (s, COOEt) ppm.- NCOO-, C(CH 3 ) 3 -signals not visible due to line broadening. k) 3-(2-tert.-Butoxycarbonyl-amino-2-carboxy-ethyl)-2,5-dihydropyrrole-l- (N,N'-di-/ert -butoxy carbonyl) carboxamidine To a solution of 267 mg (0.63 mmol) 3-(2-tert.-butoxycarbonyl-amino-2- ethoxycarbonyi-ethyl)-2,5-dihydropyrroie-l-(N,N'-di-tert.-butoxycarbonyl) carboxamidine in 5 ml THF/methanol/water 3 : 1 : 1 was added 50 mg (1.2 mmol) LiOH*H 2 O. After 30 min stirring at room temperature no starting material could be detected by TLC. The mixture was made acidic by addition of IN HC1, diluted with water and extracted three times with ether. The combined organic extracts were washed with brine, dried over MgSO and evaporated. The residue was purified by flash- chromatography to give 98 mg (31 %) of 3-(2-/ert.-Butoxycarbonyl-amino-2-carboxy- ethyl)-2,5-dihydropyrrole-l-(N,N'-di-tert.-butoxycarbonyi) carboxamidine (Boc- Ada(Boc 2 )-OH) as a colorless amorphous solid. l H-NMR (CDC13, 300 MHz) δ - 1.39, 1.44 [2s, 9H, 18H, C(CH 3 ) 3 ], 2.49 - 2.67 (br. m, 2H, 3-CH 2 -),4.33 (br. m, 4H, 2-H, 5-H), 5.30 (br. d, 1H, CHNH), 5.56 (br. s, 1H, 4-H) ppm. ,3 C-NMR (CDC13, 75 MHz) δ = 27.7, 28.9, 28.0 [3q, CCEHΛ], 31-3 (t, 3-CH 2 ), 52.0 (d, CHNH), 55.3, 56.9 (2t, C- 2, C-5), 80.0, 80.9 [2s, (C(CH 3 ) 3 ], 121.1 (d, C-4), 133.6 (s, C-3), 153.2 (s, N=C-N), 155.2 (br. s, NCOO), 176.5 (s, COOH) ppm. Example 2 (±)-3-(2-Fluorenylmethoxycarbonyl-amino-2-hydroxycarbonyl-ethyl)-2,5- dihydropyrrole-l-(N,N'-di-tert-butoxycarbonyi) carboxamidine [Fmoc-Ada(Boc) 2 OHl a) (±)-3-(2-Benzhydrylidene-2-/ert.-butoxycarbonyi-ethyl-2,5-dihydropyrrole- 1 -carboxylic acid tert. butyl ester To a solution of lithium hexamethyldisilazide [freshly prepared at 0 °C from 1.53 g (9.5 mmol) hexamethyldisilazane and 4.09 g (9.5 mmol) n-BuLi, (2.32 mmol/g in hexanes)] in 20 ml THF was added at - 78 °C a solution of 2.79 g (9.5 mmol) ten. butyl-N- (diphenyimethylene)-glycinate in 20 ml THF. The orange enolate solution was stirred for 30 min at -78 °C, then a solution of 2.70 g (8.6 mmol) 3-acetoxymethyl-2,5-dihydro- pyrrole- 1 -carboxylic acid tert. -butylester and 243 mg (0 21 mmol) Pd(PPh?) 4 in 20 mi THF was added dropwise. The reaction mixture was allowed to warm to room temperature over and was stirred for additional 12 h. The mixture was diluted with ether and quenched by addition of sat. NH 4 CI. The organic layer was washed with sat. NH4CI and brine, dried over MgSO 4 and evaporated. Purification by flash chromatography (ethyl acetate petrol ether 1:10 + 0.5 % triethylamine) gave 3.70 g (90 %) 3-(2- benzhydrylidene-2-/ert.-butoxycarbonyl-ethyl-2,5-dihydropyrrole- 1 -carboxylic acid tert. butyl ester as a slightly yellow oil. l H-NMR (CDC1 3 , 300 MHz) d = 1.41, 1.42 [2s, 9H each, C(CH 3 ) 3 ], 2.62 - 2.71 (m, 2H, 3-CH 2 -), 3.80 - 4.10 (br. m, 4H, 2-H, 5-H, CHN), 5.41 (br. m, 1H, 4-H), 7.09 - 7.81 (m, 10 H, Ar-H) ppm. 13 C-NMR (CDC1 3 , 75 MHz) d = 27.8, 28.3 [2q, C(CH 3 ) 3 ], 33.0 (t, 3-CH 2 ), 52.7, 53.1. 54.5, 55.0 (4t, C-2, C-5)*, 64.2, 64.4 (2d, CH-NH 2 )*, 78.9 [s, C(CH 3 ) 3 ], 81.07, 81.13 [2s, £(CH 3 ) 3 ]*, 121.4, 121.5 (2d, C-4)*, 127.5, 127.6, 128.1, 128.2, 128.3, 128.4, 128.6. 128.7 130.1 (9d, Ar-CH)*, 135.8, 135.9, 136.1 (3s, Ar-C)*, 139.2, 139.3 (s, C-3)*, 153.8, 153.9 (2s, NCOO)*, 170.1, 170.2 [2s, ς(CH 3 ) 3 ] 170.4 (s, N=CPh 2 ) ppm. HR-MS (FAB ) [M * +H] C 2 H 37 N 2 O 4 calc: All.215 found: 477. 769 [M τ +Na] C 2 H 36 N 2 O 4 Na calc: 499.2573 found: 499.2570 b) (±)-3-(2-Aπrino-2-tert.-butoxycarbonyl-ethyl)-2.5-dihydropyrroIe-l- carboxyiic acid tert.-butyl ester To a solution of 1.57 g (3.3 mmol) 3-(2-benzhydrylidene-2-tert.-butoxycarbonyl-ethyl- 2,5-dihydropyrrole-l -carboxylic acid tert. butyl ester in iO ml THF and 5 ml water was added 5 ml glacial acetic acid and the mixture was stirred overnight at room temperature. THF was evaporated in vacuo, the residue was diluted with water and made alkaline by cautious addition of solid K2CO3 (or NHj solution). The mixture was extracted three times with ethyl acetate and dried over MgSO 4 . Purification by flash chromatography (elution with CH 2 Cl 2 /MeOH 20 : 1) gave 1.03 g (100 %) 3-(2-amino-2-tert.- butoxycarbonyl-ethyl)-2,5-dihydropyrrole-l -carboxylic acid t .-butyl ester as a colorless, waxy solid. Η-NMR (CDCI 3 , 300 MHz) d = 1.41, 1.42 [2s, 9H each, C(CH 3 ) 3 ], 2.35 (dd, 2 J= 14.6 Hz, V= 7.4 Hz, 1H, CH,HbCHNH 2 ), 2.49 (dd, 2 J= 14.6 Hz, 3 J= 5.8 Hz, 1H. CH,HbCHNH 2 ), 3.44 (dd, 3 J = 7.4, 5.8 Hz, 1H, 4.04 ( m, 4H, 2-H, 5-H), 5.49 (br. , IH, 4-H) ppm. l3 C-NMR (CDCU, 75 MHz) d = 27.8, 28.3 [2q, C(CJχ 3 ) 3 ], 34.46, 34.52 (2t, 3-CH 2 )*, 52.7, 53.0, 54.4, 54.6 (4d, C-2, C-5)*, 53.2 (d, CHNH 2 ), 79.0, 79.1, 81.18, 81.23 [4s, C(CH,) 3 ]*, 121.6, 122.0 (2d, C- 4)*, 135.4, 135.6 (2s, C-3)*, 153.9 (s, NCOO), 174.2 (s, COOtBu) ppm. HR-MS (FAB * ) [M * +H] C i 6 H 29 N 2 O 4 calc. : 313.2127 found: 313.2095 c) (±)-3-[2-(9-Fluorenyimethoxycarbonyi-amino)-2-tert.-butoxycarbonyl- ethyI]-2,5-dihydropyrrole-l-carboxylic acid terr.-butyl ester To a ice-cooled solution of 1.03 g (3.3 mmol) 3-(2-amino-2-tert.-butoxycarbonyl-ethyl)- 2,5-dihydropyrrole-l -carboxylic acid tert.-butyi ester and 0.46 g (4.3 mmol) diisopropyl ethylamine 15 mi THF was added 0.98 g (3.8 mmol) 9-fluorenylmethyl chloroformiate in one portion. The mixture was stirred at room temperature overnight. The mixture was diluted with ether, poured on ice-water and the aqueous layer was extracted three times with ether. The combined organic layers were dried (MgSO 4 ) and evaporated. Purification by flash chromatography (ethyl acetate petrol ether 1 : 3) gave 1.70 g (97 %) 3-[2-(9-fluorenylmethoxycarbonyl-amino)-2-/ert.-butoxycarbonyl-ethyl]-2,5- dihydropyσole- 1 -carboxyiic acid tert.-butyl ester as a colorless, amorphous solid. Η-NMR (CDCK, 300 MHz) d = 1.45 [s, 9H, C(CH 3 ) 3 ], 2.48 - 2.70 (br. m, 2H, CH 2 CHNH2), 4.05 (br. m, 4H, 2-H, 5- H), 4.20 (t, IH, CHCH 2 O), 4.41 (br. m, 3H, CHNH, CHCHαO), 5.36 (br. m, IH, NH), 5.49 (br. m, IH, 4-H), 7.27 - 7.40 (m, 4H, Ar-H), 7.56 - 7 61 (m, 2H, Ar-H), 7.73 - 7.76 (m, 2H, Ar-H) ppm. 13 C-NMR (CDCU, 75 MHz) d = 27.7, 28.3 [2q, C(CH 3 ) 3 ], 31.9, 32.2 (2t, 3-CH 2 )*, 46.9 (d, £HCH 2 O), 52.6 (d, CHNH 2 ), 52.7, 53.0, 54.6 (lbr. d, 2d, C-2, C-5)*, 66.7 (t, CHCH 2 O), 79.1, 79.2, 82.46, 82.51 [4s, C(CH 3 ) 3 ]*, 119.8 (d, Ar-CH), 122.4, 122.8 (2d, C-4)*, 124.8, 127.3, 127.5 (3d, Ar-CH), 134.3 (br. s, C-3), 141.1, 143.6 (2s, Ar-C) 153.9, 155.4 (2s, NCOO), 170.5 (s, COOtBu) ppm. HR-MS (FAB * ) [M * ] C 3l H 3 gN 2 O 6 calc.:535.2808 found: 535.2789 [M * +Na] C 31 H 3g N 2 θ 6 Na calc: 557.2628 found: 557.2643 d) (±)-3-(2,5-Dihydro- 1 H-pyrrol-3-yi)-2-fluoreny imethoxycarbonylamino- propionic acid hydrochloride To a solution of 588 mg (1.1 mmol) 3-[2-(9-fluorenylmethoxycarbonyl-amino)-2-/ert.- butoxycarbonyl-ethyl]-2, 5 -dihydropyrrole-1 -carboxylic acid tert. -butyl ester and 376 mg (4 mmol) ethylene dithiol in 5 ml dioxane was added 5 ml 4N HCl in dioxane and the mixture was stirred at room temperature overnight. After 30 min a colorless solid began to precipitate. 20 ml of ether was added, the solid was filtered off, washed thoroughly with ether and dried in vacuo to give 433 mg (95 %) (=-)-3-(2,5-dihydro-lH-pyrrol-3-yl)- 2-fluorenylmethoxycarbonylamino-propionic acid hydrochloride as a slightly colored powder. 'H-NMR (CDjOD, 300 MHz) d = 2.56 - 2.80 (m, 2H, CH 2 CHNH 2 ), 3.99 (br. s, 4H, 2-H. 5-H), 4.21 (t, IH, CHCH 2 O), 4.31 - 4.42 ( m, 3H, CHNH, CHC O), 5.36 (br. m, IH. NH), 5.62 (br. s, IH, 4-H), 7.28 - 7.41 (m, 4H, Ar-H), 7.63 - 7.68 (m, 2H, Ar-H), 7.77 - 7.80 (m, 2H, Ar-H) ppm. 13 C-NMR (CD 3 OD, 75 MHz) d = 31.5, (t, £H 2 CHNH), 48.3 (d, £HCH 2 O), 53.3, 53.5, 54.1 (3d, 2d, C-2, C-5, CHzCHNH), 67.9 (t, CHCH 2 O), 120.9 (d, Ar-CH), 122.0 (d, C-4), 126.2, 128.1, 128.8 (3d, Ar-CH), 136.6 (s, C-3), 142.6., 145.2 (2s, Ar-C), 158.5 (s, NCOO), 174.4 (s, COOH) ppm. e) (±)-3-(2-Fluorenylmethoxycarbonyl-amino-2-hydroxycarbonyl-ethyl)-2,5- dihydropyrroie-l-(N,N'-di-tert-butoxycarbonyl) carboxamidine To a suspension of 400 mg (0.96 mmol) (±)-3-(2,5-dihydro-lH-pyrrol-3-yl)-2- fluorenylmethoxycarbonylamino-propionic acid hydrochloride in 5 ml acetonitrile were added 258 mg (2 mmol) ethyl diisopropylamine, followed by 298 mg (0.96 mmol) N,N'- bis-fert.-butyloxycarbonyl-lH-pyrazole-l-carboxamidine. The heterogenous mixture was stirred at room temperature overnight and was then diluted with ethyl acetate. The mixture was acidified with acetic acid and water was added. The aqueous layer was extracted three times with ethyl acetate, the combined organic layers were washed with brine, dried and evaporated to dryness. Flash chromatography (petrol ether/ethyl acetate 1 : 1 + 1 % acetic acid gave 123 mg (21 %) (±)-3-(2-fluorenylmethoxycarbonyl-amino- 2-hydroxycarbonyl-ethyl)-2,5-dihydropyrrole-l-(N,N'-di-tert.-butoxycarbonyl) carboxamidine as a slightly yellow amorphous solid. Η-NMR (CDjOD, 300 MHz) d = 1.45 [s, 18H, C(CH 3 ) 3 ], 2.57 - 2.79 (br. m, 2H, CHJCHNHJ), 4.05 (br. m, 4H, 2-H, 5-H), 4.20 (t, IH, CHCH 2 O), 4.41 (br. m, 3H, CHNH, CHC&O), 5.36 (br. m, IH, NH), 5.49 (br. m, IH, 4-H), 7.24 - 7.37 (m, 4H, Ar-H), 7.54 - 7.57 (m, 2H, Ar-H), 7.70 - 7.73 (m, 2H, Ar-H) ppm. "C-NMR (CD 3 OD, 75 MHz) d - 27.7, 27.9 [2q, C(£H 3 ) 3 ], 31.3 (t, £H 2 CHNH), 46.9 (d, £HCH 2 O), 52.6 (d, CH J CHNH), 55.5, 57.0 (2d, C-2, C-5), 66.8 (t, CHQH 2 O), 81.1 [br s, £(0 * 3)3], H9.7 (d, Ar-CH), 121.2 (d, C-4), 124.9, 126.9, 127.5 (3d, Ar-CH), 133.6 (s, C-3), 141.1, 143.6 (2s, Ar-C) 153.0, 155.8 (2s, NCOO), 176.5 (s, COOtBu) ppm. HR MS ζFAB * ) [M * ] C 33 H 4 ,N 4 O 8 calc: 621.2924 found: 621.2881 Example 3 Ada-SAW The title compound was synthesized by solid-phase methodology on a SyRo II multiple peptide synthesizer (MultiSynTech, Bochum) on a 0.03 mmol scale using Fmoc-L-Trp- trityl-polystyrene(l%)divinylbenzene resin (Fmoc-L-Trp-TCP; loading: 0.57 mmol g; PepChem, Tubingen) as starting material. The α-amino groups of the proteinogenic amino acids Ala and Ser were protected by 9-fluorenylmethoxycarbonyl (Fmoc), the side chain hyrdroxy group of Ser by tert. -butyl. The non-proteinogenic amino acid Ada was used as Boc-Ada(Boc 2 )-OH (from example 1 ). The Fmoc-protected amino acids were coupled in a 6-fold excess for 30 min in DMF. TBTU (1 eqj and NMM (1 eq) were used as activating reagents. Cleavage of the Fmoc group was carried out in piperidine/dimethylformamide (1 : 1 v/v) for 2 x 10 min. Coupling of Boc-Ada(Boc 2 )-OH was performed manually in DMF within 1 h by using 0.048 mmol of the protected amino acid ( 1.65-fold excess) and equimolare amounts of TBTU and NMM for activation. The peptide was cleaved from the resin with 750 ul of acetic acid/trifluoroethanol/dichloromethane (30:10:70) within 2 h. After washing five times with 150 ul of the same solvent mixture the filtrates were combined, diluted with 10 ml heptane and concentrated. This procedure was repeated twice in order to remove the acetic acid completely. The oily residue was dissolved in 5 ml 4 N hydrogen chloride in dioxane. To this solution 270 ul ethanedithiol were added and the mixture was stirred for 3 h at room temperature. Then the solvent was removed and the residue dissolved in heptane and concentrated again several times until the ethanedithiol was almost completely removed. The crude peptide was lyophilized from tert. -butanol/water (1:1) and purified by preparative HPLC to yield 9.5 mg Ada-SAW as colorless lyophilisate (purity by HPLC >90%). ESI-MS: m z 543.3 M * Example 4 Ada-Ava-W The title peptide was prepared in the same manner as example 3 starting from 50 mg (0.03 mmol) Fmoc-L-Trp-TCP resin using Fmoc protected aminovaleric acid. Yield: 6.2 mg Ada-Ava-W as colorless lyophilisate (purity by HPLC >90%). ESI-MS: m/z 484.3 M * Example 5 Ada-Aba-W The title peptide was prepared in the same manner as example 3 starting from 50 mg (0.03 mmol) Fmoc-L-Trp-TCP resin using Fmoc protected aminobutyric acid. Yield: 4.8 mg Ada-Aba-W as colorless lyophilisate (purity by HPLC >90%). ESI-MS: m/z 470.3 M + Example 6 T-Ada-SAW The title compound was synthesized by solid-phase methodology on a SyRo II multiple peptide synthesizer (MultiSynTech, Bochum) on a 0.03 mmol scale using Fmoc-L-Trp- trityl-polystyrene(l%)divinylbenzene resin (Fmoc-L-Trp-TCP; loading: 0.57 mmol g; PepChem, Tubingen) as starting material. The α-amino groups of the proteinogenic amino acids Ala and Ser were protected by 9-fluorenylmethoxycarbonyl (Fmoc), the side chain hydroxy group of Ser by tert. -butyl. The non-proteinogenic amino acid Ada was used as Fmoc-Ada(Boc 2 )-OH (from example2). The Fmoc-protected amino acids were coupled in a 6-fold excess for 30 min in DMF. TBTU (1 eq) and NMM (1 eq) were used as activating reagents. Cleavage of the Fmoc group was carried out in piperidine/dimethylformamide (1 :1 v/v) for 2 x 10 min. Coupling of Boc-Ada(Boc 2 )-OH and Thr was performed manually in DMF within 1 h by using 0.048 mmol of the protected amino acid Boc-Ada(Boc 2 )-OH (1.65-fold excess) and a 6 fold excess in the case of Thr. Equimolar amounts of TBTU and NMM were used for activation. The peptide was cleaved from the resin with 750 ul of acetic acid/trifluoroethanol/dichloromethane (30:10:70) within 2 h. After washing five times with 150 ul of the same solvent mixture the filtrates were combined, diluted with 10 ml heptane and concentrated. This procedure was repeated twice in order to remove the acetic acid completely. The oily residue was dissolved in 5 ml 4 N hydrogen chloride in dioxane. To this solution 270 ul ethanedithiol were added and the mixture was stirred for 3 h at room temperature. Then the solvent was removed and the residue dissolved in heptane and concentrated again several times until the ethanedithiol was almost completely removed. The crude peptide was lyophilized from tert.-butanol/water (1:1) and purified by preparative HPLC to yield 2.6 mg T-Ada-SAW as colorless lyophilisate (purity by HPLC >98%). ESI-MS: m z 644.3 M * Example 7 T-Ada-Ava-W The title peptide was prepared in the same manner as example 6 starting from 50 mg (0.03 mmol) Fmoc-L-Trp-TCP resin using Fmoc protected aminovaleric acid. Yield: 2.7 mg T-Ada-Ava-W as colorless lyophilisate (purity by HPLC >95%). ESI-MS: m z 585.3 M * Example 8 T-Ada-Aba-W Tlw title peptide was prepared in the same manner as example 6 starting from 50 mg (0.03 mmol) Fmoc-L-Trp-TCP resin using Fmoc protected aminobutyric acid. Yield: 2.7 mg T-Ada-Aba-W as colorless lyophilisate (purity by HPLC >95%). ESI-MS: m/z 585.3 M * Example 9 Biological activity Compounds of general formula (I) were tested in an in vitro DNA-synthesis assay. The cells used were primary cultures of osteoblasts from fetal rat calvarias. The experiments were performed in an analogous manner as published in Pfeilschifter et al., Endocrinology 126, 703 (1990).

Claims: Claims 1. Compounds of general formula (I) wherein R], R2, R3 and X may be the same or different, and wherein Ri, R2 represent hydrogen, an amino acid,- peptidyl, alkyl or aryl residue; R3 represents hydroxy, lower alkoxy, or an -NR3i 32 residue. where R3 1 , R32 and represent idependently hydrogen, an aminoacid, peptidyl, alkyl or aryl residue; X represents an amino acid or a peptide; R4 represents hydrogen, hydroxy, amino or Cι-C 4 -alkyl: m represents a number between 0 and 5; R5 represents an optionally substituted saturated or unsaturated mono- or bicyclic moiety which may contain one or more heteroatoms, a C i -C j 1 alkyl group which may have substitutions or intermittent heteroatoms. their tautomers, optical isomers, pharmaceutically acceptable salts and prodrugs. 2. Compound of general formula I of claim 1, wherein i and R 2 are hydrogen. 3. Compound of general formula I of any one of the claims 1 - 2, wherein R3 represents hydroxy or amino. 4. Compound of general formula I of any one of the claims 1 - 3, wherein R4 represents hydroxy or methyl. 5. Compound of general formula I of any one of the claims 1 - 4, wherein m represents a number 1, 2, or 3. 6. Compound of general formula I of any one of the claims 1 - 4, wherein (CHR4)mR 5 represents a residue attached to Cα of a proteinogenic or non- proteinogenic amino acid. 7. Compounds of general formula (IV) wherein R $ represents a protecting group, e.g., the benzoyi group, an alkyloxycarbonyl group or the benzyloxycarbonyl group R represents Fmoc or an other protecting group useful for orthogonal syntheses Y represents COOH or COO-d-C 4 -alkyl. 8. A pharmaceutical product comprising at least one of the compounds of general formula I of any one of the claims 1 to 6. 9. Use of a compound of general formula I of any one of the claims 1 to 6 in a method for the preparation of a medicament for treating of bone disorders.

Inventors: ESSWEIN ANGELIKA, HOFFMANN EIKE, KLING LOTHAR, KONETSCHNY-RAPP SILVIA, ESSWEIN, ANGELIKA, HOFFMANN, EIKE, KLING, LOTHAR, KONETSCHNY-RAPP, SILVIA
Applicants: ESSWEIN ANGELIKA, HOFFMANN EIKE, KLING LOTHAR, KONETSCHNY RAPP SILVIA, ROCHE DIAGNOSTICS GMBH, ESSWEIN, ANGELIKA, HOFFMANN, EIKE, KLING, LOTHAR, KONETSCHNY-RAPP, SILVIA
Application year: 1998
Main classification: C07K14
IPC codes: A61K38, A61P3, A61P19, C07D207, C07D403, C07K5, C07K14